
Forever chemicals now linked to disease suffered by 35million Americans
Researchers from Mount Sinai looked at the link between polyfluoroalkyl substances (PFAS) - found in everything from non-stick cookware to food packaging to tap water - and the incidence of type 2 diabetes, which affects up to 35 million Americans.
Past research has linked the chemicals, which accumulate in the body over time and are slow to break down, to a range of health problems, including kidney, breast and testicular cancers.
To paint a more comprehensive picture of PFAS and diabetes risk, researchers looked at large population-level datasets to identify patterns of exposure and illness.
Based on available data, the study analyzed 180 people recently diagnosed with type 2 diabetes and compared them to 180 similar individuals without diabetes. All participants were matched based on age, sex, and ancestry.
Researchers used blood samples to analyze PFAS levels and found that higher levels increased the risk of developing type 2 diabetes by almost one third.
Specifically, each increase in range of PFAS exposure was linked to a 31 percent increase in risk.
Dr Vishal Midya, who was the lead author of the study and an assistant professor of environmental medicine at Mount Sinai, said: 'Because they don't break down easily, PFAS accumulate in the environment - and in human bodies.
'Our study is one of the first to examine how these chemicals may disrupt the body's metabolism in ways that increase diabetes risk - particularly in diverse US populations.'
For the study, the researchers used data from BioMe, an electronic health record-linked biobank of more than 65,000 patients seeking primary care at Mount Sinai Hospital in New York since 2007.
From an initial analysis, 180 people recently diagnosed with type 2 diabetes were selected with this group made up of 33 percent African Americans, 33 percent Hispanics, and 33 percent Whites.
These patients were then compared to 180 similar individuals without diabetes. All participants were matched based on age, sex, and ancestry.
Blood plasma samples collected from the individuals before they were diagnosed with diabetes or given the all-clear were used to assess PFAS levels.
The researchers then applied Weighted Quantile Sum (WQS) regression to the samples. This statistical method is used to analyze the effects of mixtures of chemical exposures on a health outcome.
By using WQS, the team were able to see how PFAS levels in the blood were linked to patients developing diabetes.
Metabolic alterations, such as insulin resistance and impaired glucose metabolism, are key contributors to the development of type 2 diabetes.
These changes, often linked to obesity and unhealthy lifestyles, disrupt the body's ability to regulate blood sugar effectively, leading to hyperglycemia.
Hyperglycemia occurs when the level of sugar in your blood gets too high. Chronic or persistent hyperglycemia can lead to diabetes, particularly type 2 diabetes.
Symptoms of hyperglycemia include feeling thirsty, frequent urination, tiredness and breath that smells fruity.
Treatment for type 2 typically involves taking insulin several times a day, either by injection or through a pump.
PFAS exposure can contribute to diabetes development through several mechanisms, including disrupting cells in the pancreas responsible for regulating blood glucose levels, increasing insulin resistance, and potentially increasing body fat.
The researchers say the new findings underscore the importance of regulating PFAS.
Senior author, Dr Damaskini Valvi, said: 'Findings can help us design more effective interventions for the early prevention of type 2 diabetes in the future, taking into account individuals' exposures to environmental chemicals along with other well-known genetic, clinical, and lifestyle factors implicated in diabetes development.
'Mounting research suggests that PFAS are a risk factor for several chronic diseases, such as obesity, liver disease, and diabetes.'
PFAS are microscopic substances that take thousands of years to break down in the environment and human body, earning them the name 'forever chemicals.'
Their main purpose is to repel water and oil, which is what makes non-stick cookware easier to clean and why certain jackets and tents can withstand rain.
The chemicals can seep into the water supply from washing dishes and can enter food if packaging is made to be grease-resistant or if the non-stick coating on pots and pans begins to deteriorate.
PFAS are also common in pesticides used on crops, which produces chemical-rich runoff that can enter the drinking water supply.
There is no level of safe exposure to the chemicals.
Public water systems have four years to implement solutions to reduce PFAS in their water, under orders made by the Environmental Protection Agency (EPA).
Beginning in 2029, the EPA will police levels of six types of PFAS in drinking water - PFOS, PFOA, PFNA, PFHxS, PFHpA, and PFBS - and systems with unacceptable levels, will be required to notify the public.
Last year, the EPA set the maximum contaminant levels for PFAS at 4.0 parts per trillion.
One study found that US counties where drinking water surpassed this level - such as Nassau, Suffolk, and Rockland in New York and Los Angeles, Orange, and Riverside counties in California - had a higher incidence of digestive, endocrine, respiratory, and mouth and throat cancers.
Increases in incidence rates ranged from slightly elevated, at two percent, to 'substantially elevated' at 33 percent.
The Mount Sinai team are now calling for studies involving larger populations, expanding over the life course, in order to better understand the health impacts of PFAS across the lifespan and at vulnerable life periods.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
2 hours ago
- Daily Mail
Menopause made my hair fall out. Then I discovered a new hair-loss solution. This is the secret ALL midlife women need to know
For me, midlife has brought various indignities, as well as many joys. But standing over a sink to count the number of hairs that had come out in my brush one morning has to be among the more distressing aspects. For the record, it was 201. And why was I counting them? Because I'd searched 'how to tell if your hair is falling out' online – and according to Dr Google, anything over 100 strands was a cause for concern.


The Independent
3 hours ago
- The Independent
WeightWatchers boss says ‘exciting work to do' amid impact of weight loss jabs
WeightWatchers was slower to adapt to the emergence of anti-obesity jabs than rivals, its boss has admitted, as the 62-year-old brand strives to catch up with rapidly evolving attitudes towards weight loss. Tara Comonte, chief executive of the US-based business, said it had a lot of work to do after going through a 'reset'. WeightWatchers recently announced it had emerged from bankruptcy after writing off a portion of the 1.15 billion US dollar (£860 million) debt on its balance sheet. It came as the business was competing with the emergence of GLP-1s – the scientific term for weight loss jabs, which work by reducing food cravings – and a new wave of apps and advice spreading on social media. Ms Comonte told the PA news agency that it 'wasn't as quick to medical weight loss solutions' as some other firms in the US, notably so-called 'telehealth' businesses that offer healthcare remotely. WeightWatchers, which runs some 20,000 workshops each month globally, is now 'at the beginning of the journey' towards forging a new place in the industry and meeting demand from current and future members, Ms Comonte said. 'This whole industry is going through somewhat of a reset and we have exciting work to do,' she told the PA news agency. 'This is a moment where, possibly more than ever before, people are talking about weight, and weight health… where people are seeking more education than ever before, and there are more voices than ever before.' Ms Comonte said the brand was known for 'trust and science' and it was important to harness that 'as there are more and more voices in the ecosystem'. WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app. It forms part of its efforts to muscle into the market by offering behavioural strategies and community-based support to people using or coming off the medication. 'There's no 'us and them' anymore,' Ms Comonte told PA, hitting back at weight loss jabs often being pitted as rivals to its model. Dr Kim Boyde, WeightWatchers' newly appointed chief medical officer, said not all its members will want or need weight loss medication – but stressed that it was 'imperative' the programme offers it to those that might benefit. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.


Reuters
4 hours ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.